Aldeyra Therapeutics shares are trading higher after the company announced plans to seek FDA review of its Complete Response Letter for dry eye disease candidate reproxalap through a Formal Dispute Resolution Request.

argenx Meets Primary Endpoint in Phase II Celiac Disease Study

argenx announced positive phase II results for FB102, an investigational therapy for celiac disease, meeting its primary endpoint with significant improvements in intestinal tissue measures versus placebo and no new safety signals. The company plans to advance FB102 into late-stage development and evaluate it for other autoimmune conditions. However, the stock declined nearly 12% following a separate announcement that argenx discontinued its phase III UNITY study for Vyvgart Hytrulo in Sjögren's disease.

HC Wainwright & Co. Reiterates Neutral on Aldeyra Therapeutics, Maintains $2 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Neutral and maintains $2 price target.

Aldeyra Fights Back Against FDA Rejection, Dispute Plan Triggers Rally

Aldeyra Therapeutics stock surges as the company files an FDA dispute resolution for its dry eye drug reproxalap following a rejection.

BTIG Reiterates Buy on Aldeyra Therapeutics, Maintains $9 Price Target